DWS has acquired RadioOnkologieNetzwerk GmbH (RON), the leading radiotherapy platform provider in Germany, on behalf of its third Pan-European Infrastructure (PEIF III) fund, in partnership with the founders, Dr Sandra Röddiger and Dr Ralf Kurek.
RON has a strong track record of providing high quality cancer care services to its patients, operating the largest radiotherapy network in Germany with 17 different sites across five states in the country. Together with DWS’s existing investment in Medipass, the combination with RON will create the leading European provider of cancer care and advanced diagnostic imaging services.
The combined company will benefit from an existing presence in Germany, Italy and the UK, offering cancer care services for patients and hospitals focused on radiotherapy and radiological imaging solutions. The group’s services will include a network of clinics, management of outsourced radiotherapy departments of hospitals and provision of managed equipment services for radiotherapy and radiology. As a long term infrastructure investor, DWS is committed to supporting the company in continued clinical and operational excellence in the treatment of patients, while also expanding rapidly to serve patients across the continent. The envisaged expansion would include both the acquisition of new clinics and organic growth via new outsourcing contracts with hospitals, in existing and new countries, such as France, Austria and Switzerland.
Hamish Mackenzie, Head of Infrastructure at DWS, says: “We are pleased to partner with Sandra, Ralf and Guglielmo to create the leading European oncology platform. We look forward to working with hospitals and clinicians across Europe to achieve our shared vision of providing an increasing number of patients with these essential high quality cancer care services across the continent.”
Sandra Röddiger and Ralf Kurek, Co-CEOs at RON added: “DWS is the ideal partner to realise our vision of providing the best possible oncological patient care. Both DWS and Medipass share our deep conviction that the combination of a management team led by doctors, cutting-edge medical technology paired with genuine empathy for our seriously ill patients are the key factors for continued successful growth.”
Guglielmo Brayda Di Soleto, CEO at Medipass, says: “Medipass is excited to join forces with RadioOnkologie Netzwerk to create the leading pan-European player in radiotherapy and radiology. Medipass and RON share a common vision and strategy, using a medical-focussed approach and state-of-the-art equipment to provide hospitals and patients with optimised treatment solutions, which will be an innovative, solid and effective support in cancer care.”